Condition: Cerebral Small Vessel Diseases · Cerebral Autosomal Dominant Arteriopathy With Subcortical Infarcts and Leukoencephalopathy · Cerebral Microbleeding · Sponsor: Mayo Clinic
Cerebral small vessel disease (SVD), present in 80-94% of adults over age 65 years, increases the risk of stroke by 2-fold, and dementia by 2.3-fold. There is currently no treatment to slow SVD progression. This study aims to test whether impaired cerebral and retinal vasoreactivity may serve as biomarker for SVD progression, and to evaluate the safety and efficacy of cilostazol (antiplatelet agent with vasodilatory and anti-inflammatory properties) for the treatment of SVD.
This description comes directly from the study's public registry record.
Meredith McDonald · 904-953-4200 · mcdonald.meredith@mayo.edu
Always discuss trial participation with your own doctor first.
| Mayo Clinic Florida | Jacksonville, Florida, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04753970